UK Biobank pharma proteomics project extended to Explore 3072 platform

July 21, 2021 It has been announced that the UK Biobank Pharma Proteomics Project (UKB-PPP Consortium) has decided to expand the ongoing proteomics study of 53,000 participants to the new Olink® Explore 3072 platform, providing access to Olink´s expanded library of approximately 3,...

Announcing Olink Explore 3072

A significantly expanded high-throughput proteomics platform, offering uncompromised data quality with coverage of all major biological pathways! We are delighted to announce that customers can now pre-order the next evolution of our Olink® Explore platform for high-throughput prot...

Announcing Olink Signature

Olink Signature Q100 A benchtop system for protein biomarker analysis Olink® Signature Q100  is a newly developed instrument for readout of Olink® Target 96/48 and Olink® Focus protein biomarker panels. This instrument provides a new, dedicated solution for qPCR readout of Olink pa...

Next generation plasma profiling to monitor health and disease – the first Olink Explore publication!

A major study from Professor Mathias Uhlén’s group at KTH in Stockholm is the first paper to be published describing a study based on the Olink® Explore 1536 platform. Using this high-throughput, high-multiplex protein biomarker discovery solution, they performed a longitudinal wellness study ...

SciLifeLab Uppsala now offering the Olink Explore platform

After the recent launch of the Olink® Explore 1536 platform as kits, one of our long-standing core facility partners has enthusiastically completed their training to become the first external Olink Explore core lab in Europe.  Uppsala SciLifeLab proteomics and NGS teams join forces ...

SelectScience Editorial Article of the Year Award

We are delighted to announce that SelectScience have announced an Olink-sponsored article from Professor Leo Joosten as their drug discovery & development editorial article of the year for 2021. In an exclusive interview with SelectScience, Professor Joosten discussed how his t...

Protected: Olink webinar May 20, 2021

“Multi-omic approaches to better understand human disease and drive future therapies” Please join us for this free webinar, at which you will learn how combining high-muliplex proteomics using Olink’s PEA technology with genetic data and other omics approaches is providing...

Olink Explore 1536 nominated for SelectScience award

February 23, 2021 Olink Explore 1536 has been nominated for the Scientists’ Choice Awards shortlist 2021 by SelectScience, in the category, “Best New Drug Discovery & Development Product of 2020“. Voting for this award is open until W...

Olink Explore available as kits

After a highly successful introduction via fee-for-service at our Olink Analysis Service labs in Uppsala and Boston, we are pleased to announce that our Olink Explore platform is now available as kits that can be run in suitably equipped and trained external labs. The platform enables high-throughpu...

Olink to provide proteomics data from 53,000 UK Biobank participants

We are proud to announce that the Olink® Explore 1536 platform, utilizing Next Generation Sequencing (NGS) as read-out, will be used in a project to measure plasma protein concentration in 53,000 individuals from the UK Biobank, one of the world’s largest genetic resources. The proj...